[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607736":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":184,"collaborators":11,"id":186,"slug":187,"hasResults":188,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":188,"sex":194,"minAge":195,"maxAge":11,"enrollmentInfo":196,"targetDuration":11,"studyType":199,"phases":200,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"Vironexis Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1\u002FGroup 2\u002FGroup 3\u002FGroup 4","EXPERIMENTAL",null,[13,14,15,16],"Genetic: Dose Level 1, VNX-202","Genetic: Dose Level 2, VNX-202","Genetic: Dose Level 3, VNX-202","Genetic: Dose Level 4, VNX-202",[18,23,26,29],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"GENETIC","Dose Level 1, VNX-202","Adeno-associated viral vector encoding the CD3\u002FHER2 Bi-Specific T-Cell Engager (AAV.CD3\u002FHER2), Single IV Infusion",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":11},"Dose Level 2, VNX-202",[9],{"type":19,"name":27,"description":21,"armGroupLabels":28,"otherNames":11},"Dose Level 3, VNX-202",[9],{"type":19,"name":30,"description":21,"armGroupLabels":31,"otherNames":11},"Dose Level 4, VNX-202",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Allen Reha","CONTACT","908-938-6019","allen.reha@vironexis.com",[39,58,73,86,97,111,125,139,154,169],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Valkyrie Clinical Trials","RECRUITING","Los Angeles","California","90067","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-118.24368,34.05223,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":56,"phoneExt":11,"email":57},"Myo Zaw","424-535-1874","clinicaltrials@vctcare.com",{"facility":59,"status":41,"city":60,"state":61,"zip":62,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"SCRI Denver DDU at HealthOne","Denver","Colorado","80218",{"type":48,"coordinates":64},[65,66],-104.9847,39.73915,{"lat":66,"lon":65},[69],{"name":70,"role":35,"phone":71,"phoneExt":11,"email":72},"Julia Etchart","805-701-0185","julia.etchart@sarahcannon.com",{"facility":74,"status":41,"city":75,"state":76,"zip":77,"country":45,"countryCode":46,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Mayo Clinic","Jacksonville","Florida","32224",{"type":48,"coordinates":79},[80,81],-81.65565,30.33218,{"lat":81,"lon":80},[84],{"name":11,"role":35,"phone":85,"phoneExt":11,"email":11},"855-776-0015",{"facility":74,"status":41,"city":87,"state":88,"zip":89,"country":45,"countryCode":46,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Rochester","Minnesota","55095",{"type":48,"coordinates":91},[92,93],-92.4699,44.02163,{"lat":93,"lon":92},[96],{"name":11,"role":35,"phone":85,"phoneExt":11,"email":11},{"facility":98,"status":41,"city":99,"state":100,"zip":101,"country":45,"countryCode":46,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Hackensack Medical Center","Hackensack","New Jersey","07601",{"type":48,"coordinates":103},[104,105],-74.04347,40.88593,{"lat":105,"lon":104},[108],{"name":11,"role":35,"phone":109,"phoneExt":11,"email":110},"551-996-1777","OncologyResearchReferral@hmhn.org",{"facility":112,"status":41,"city":113,"state":113,"zip":114,"country":45,"countryCode":46,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":48,"coordinates":116},[117,118],-74.00597,40.71427,{"lat":118,"lon":117},[121],{"name":122,"role":35,"phone":123,"phoneExt":11,"email":124},"Jamie Walters","917-843-7966","waltersj@mskcc.org",{"facility":126,"status":41,"city":127,"state":128,"zip":129,"country":45,"countryCode":46,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":48,"coordinates":131},[132,133],-81.69541,41.4995,{"lat":133,"lon":132},[136],{"name":11,"role":35,"phone":137,"phoneExt":11,"email":138},"866-223-8100","canceranswer@ccf.org",{"facility":140,"status":41,"city":141,"state":142,"zip":143,"country":45,"countryCode":46,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Thomas Jefferson University, Sidney Kimmel Cancer Center","Philadelphia","Pennsylvania","19107",{"type":48,"coordinates":145},[146,147],-75.16362,39.95238,{"lat":147,"lon":146},[150],{"name":151,"role":35,"phone":152,"phoneExt":11,"email":153},"Steven Manobianco, MD","215-955-8874","steven.manobianco@jefferson.edu",{"facility":155,"status":41,"city":156,"state":157,"zip":158,"country":45,"countryCode":46,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":48,"coordinates":160},[161,162],-86.78444,36.16589,{"lat":162,"lon":161},[165],{"name":166,"role":35,"phone":167,"phoneExt":11,"email":168},"SCRI Referrals","615-329-7274","SCRI.DDUreferrals@scri.com",{"facility":170,"status":41,"city":171,"state":172,"zip":173,"country":45,"countryCode":46,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":48,"coordinates":175},[176,177],-95.36327,29.76328,{"lat":177,"lon":176},[180],{"name":181,"role":35,"phone":182,"phoneExt":11,"email":183},"Christine Tran","713-794-1354","cmtran@mdanderson.org",{"type":185,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607736","phase-1-gene-therapy-for-her-positive-cancer-sentry-her2-100607736",false,"NCT07192432","Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","A Phase 1\u002F2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer","SENTRY-HER2","Inclusion Criteria:\n\n* Age: ≥18 years of age\n* Histologically or cytologically confirmed diagnosis of HER-2 positive solid tumor as defined in the protocol\n* Part 1: presence of advanced or metastatic disease that has progressed during or following previous treatment\n* Part 2: Early stage HER-2 positive cancers with high risk for relapse following completion of SOC or after neoadjuvant systemic treatment\n* AAV specified capsid total antibody ≤1:400\n* ECOG performance status of 0 or 1\n* Life expectancy ≥3 months\n* Protocol-specified ranges for renal, liver, cardiac and pulmonary function\n* Protocol-specified ranges for hematology parameters\n\nExclusion Criteria:\n\n* Hepatoxicity (AST or ALT \\> 2x upper limit of normal)\n* Known active CNS or leptomeningeal disease\n* History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy\n* Pregnant or nursing (lactating) women\n* History of other malignancy within 5 years prior to screening as defined in protocol\n* History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity Concurrent anti-cancer treatment in another investigational trial","ALL","18 Years",{"count":197,"type":198},27,"ESTIMATED","INTERVENTIONAL",[201,202],"PHASE1","PHASE2","This is a Phase 1\u002F2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.",[205],"HER2 Expressing Solid Tumors",[207,208,209,210],"HER2+ breast cancer","HER2+ gastric cancer","Other HER+ cancer","HER2-low cancer","2026-06-22",{"date":213,"type":214},"2026-06-24","ACTUAL",{"date":216,"type":214},"2025-11-18",{"date":218,"type":198},"2033-10",{"name":5,"class":6},10]